The global antiviral drugs market size is expected to reach USD 46.9 billion by 2027, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of -2.3% over the forecast period. Increasing geriatric population is considered to be the major factor anticipated to drive the demand for efficient treatment of human immunodeficiency virus (HIV) infections.
According
to the Centers of Disease Control and Prevention (CDC), nearly half the people
diagnosed with HIV in U.S. are aged 50 and older. Furthermore, according to the
data published in World Population Prospects: The 2019 Revision, one in six
people globally is estimated to be over age of 65 years by 2050. In addition,
one in four persons living in Northern America and Europe would be aged 65
years and above by 2050. The number of persons aged 80 years and above is
estimated to triple, from 143 million in 2019 to 426 million in 2050. The
increasing aging population worldwide would have a direct impact on the
healthcare systems, who would have to meet the needs of the aging population.
This, in turn, would drive the demand for antiviral drugs, which can be used to
treat a range of viral infections.
Presence
of pipeline antiviral products for HIV therapeutics is anticipated to drive the
market over the forecast period. For instance, ViiV Healthcare is developing
Cabotegravir/rilpivirine (long-acting injectable), which is currently under
Phase III and are types of NNRTI/ INSTI drug class. In addition,GS-6207 (capsid
inhibitor) and vesatolimod (TLR-7 agonist) are being developed by Gilead
Sciences and are currently under Phase I trial for the treatment of HIV.
Moreover, advancements in epidemiology and growing awareness of viral diseases
are expected to result in a high demand for efficient treatment solutions.
According
to the CDC, the prevalence of oral herpes (HSV-1) and genital herpes (HSV-2)
was 47.8% and 11.9% respectively, from 2015 to 2016. The Herpes Resource Center
(HRC) provides public awareness, education, and patient support. Moreover, the
Hepatitis B Foundation provides information such as diagnosis, preventive
measures, and treatment. Increasing preventive measures with the availability
of various vaccines is expected to hinder the market growth over the forecast
period.
Full Research Report On Antiviral Drugs Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/antiviral-drugs-market
Further key
findings from the report suggest:
- Reverse transcriptase inhibitors held the largest
share in 2019 and is estimated to be the fastest-growing segment over the
forecast period as these inhibitors slow down or prevent viral replication
- DNA polymerase inhibitors was the second-largest
segment in 2019 owing to its effectiveness in combating drug resistance
- Generic products are estimated to be the
fastest-growing segment over the forecast period owing to increased
adoption of generic drugs in developing countries
- Hepatitis dominated the application segment in
2019 owing to the availability of various antiviral products for its
treatment
- HIV is estimated to be the fastest-growing
segment over the forecast period due to its increasing prevalence and
incidence rate
- North America dominated the global antiviral
drugs market in 2019 owing to the presence of key players in the region
and the availability of a well-established healthcare infrastructure.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/antiviral-drugs-market/request/rs1
Grand View Research has
segmented the global antiviral drugs market on the basis of drug class, type,
application, and region:
Antiviral Drug
Class Outlook (Revenue, USD Billion, 2016 - 2027)
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Neuraminidase Inhibitors
- Others
Antiviral Drugs
Type Outlook (Revenue, USD Billion, 2016 - 2027)
- Branded
- Generics
Antiviral Drugs
Application Outlook (Revenue, USD Billion, 2016 - 2027)
- HIV
- Hepatitis
- Herpes
- Influenza
- Others
Antiviral Drugs
Regional Outlook (Revenue, USD Billion, 2016 - 2027)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- UAE
- Saudi Arabia
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment